on malignant glioma cells

Cyclin-dependent kinase inhibitors (CDKIs) are considered as novel anticancer agents because of their ability to induce growth arrestor apoptosis in tumour cells. It has not yet been fully determined, however, which CDKI is the best candidate for the treatment ofmalignant gliomas and whether normal brain tissues are affected by CDKI expression. Using recombinant adenoviral vectors thatexpress CDKIs (p16